Pharvaris (PHVS) CCO reports initial stock, RSU and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Pharvaris N.V. Chief Commercial Officer Wim Souverijns filed a Form 3 reporting his initial equity holdings in the company. As of March 18, 2026, he holds 55,111 shares of common stock directly, including restricted stock units that settle in common shares.
He also reports multiple stock option awards on common stock, such as 55,000 underlying shares at an exercise price of 28.0000 per share expiring on March 3, 2036, and 75,000 underlying shares at 8.0500 per share expiring on April 6, 2033. Footnotes describe time-based vesting schedules, typically with 25% vesting on a specified date and the remainder vesting in equal monthly installments over 48 months.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Souverijns Wim
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 55,000 shares (Direct);
Common Stock — 55,111 shares (Direct)
Footnotes (1)
- Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -18,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -7,708 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.
FAQ
What does the Pharvaris (PHVS) Form 3 filing by Wim Souverijns report?
The Form 3 reports Chief Commercial Officer Wim Souverijns’ initial equity holdings in Pharvaris. It lists his common stock position and several stock option grants and restricted stock units with specified exercise prices, vesting schedules, and expiration dates as of March 18, 2026.
What stock option awards are reported for Wim Souverijns in Pharvaris (PHVS)?
The filing shows several stock option awards on Pharvaris common stock. Examples include 55,000 underlying shares at 28.0000 per share expiring March 3, 2036, and 75,000 underlying shares at 8.0500 per share expiring April 6, 2033, all held directly by Souverijns.
How do Wim Souverijns’ Pharvaris (PHVS) stock options vest?
Footnotes state each option grant vests 25% on a specified initial vesting date, with the remaining shares vesting in 1/48 monthly installments. For example, options expiring July 1, 2032 and April 6, 2033 each had 25% vest earlier, with the balance vesting monthly thereafter.
What restricted stock units (RSUs) are disclosed for Wim Souverijns at Pharvaris (PHVS)?
The filing notes RSUs from awards granted on March 3, 2026, March 12, 2025, and April 11, 2024. Each grant vests 25% on its one-year anniversary date, with remaining units vesting monthly. All RSUs settle in Pharvaris common stock and are included in his reported share holdings.
Does the Pharvaris (PHVS) Form 3 show any stock purchases or sales by Wim Souverijns?
The Form 3 functions as an initial ownership report and shows holdings only. The transaction summary indicates no buy, sell, exercise, gift, or tax-withholding transactions; it simply lists existing common stock, RSUs, and stock option positions as of March 18, 2026.